| |
 Online-Ressource | |
| Verfasst von: | Bärtsch, Marc-Andrea [VerfasserIn]  |
| Schlenzka, Jana [VerfasserIn] | |
| Hielscher, Thomas [VerfasserIn] | |
| Raab, Marc-Steffen [VerfasserIn] | |
| Sauer, Sandra [VerfasserIn] | |
| Merz, Maximilian [VerfasserIn] | |
| Mai, Elias K. [VerfasserIn] | |
| Müller-Tidow, Carsten [VerfasserIn] | |
| Luntz, Steffen P. [VerfasserIn] | |
| Jauch, Anna [VerfasserIn] | |
| Brossart, Peter [VerfasserIn] | |
| Görner, Martin [VerfasserIn] | |
| Klein, Stefan [VerfasserIn] | |
| Glaß, Bertram [VerfasserIn] | |
| Reimer, Peter [VerfasserIn] | |
| Graeven, Ullrich [VerfasserIn] | |
| Fenk, Roland [VerfasserIn] | |
| Hänel, Mathias [VerfasserIn] | |
| Metzler, Ivana von [VerfasserIn] | |
| Lindemann, Hans W. [VerfasserIn] | |
| Scheid, Christoph [VerfasserIn] | |
| Blau, Igor-Wolfgang [VerfasserIn] | |
| Salwender, Hans [VerfasserIn] | |
| Noppeney, Richard [VerfasserIn] | |
| Besemer, Britta [VerfasserIn] | |
| Weisel, Katja [VerfasserIn] | |
| Goldschmidt, Hartmut [VerfasserIn] | |
| Titel: | Salvage autologous transplant in relapsed multiple myeloma |
| Titelzusatz: | long-term follow-up of the phase 3 GMMG ReLApsE trial$dbrief report : clinical trials and observations |
| Verf.angabe: | Marc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, Marc S. Raab, Sandra Sauer, Maximilian Merz, Elias Karl Mai, Carsten Müller-Tidow, Steffen Luntz, Anna Jauch, Peter Brossart, Martin Goerner, Stefan Klein, Bertram Glass, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Ivana von Metzler, Hans W. Lindemann, Christof Scheid, Igor-Wolfgang Blau, Hans J. Salwender, Richard Noppeney, Britta Besemer, Katja C. Weisel, and Hartmut Goldschmidt, for the German-Speaking Myeloma Multicenter Group |
| E-Jahr: | 2025 |
| Jahr: | 17 April 2025 |
| Umfang: | 8 S. |
| Illustrationen: | Diagramme |
| Fussnoten: | Gesehen am 03.06.2025 |
| Titel Quelle: | Enthalten in: Blood |
| Ort Quelle: | Washington, DC : American Society of Hematology, 1946 |
| Jahr Quelle: | 2025 |
| Band/Heft Quelle: | 145(2025), 16 vom: Apr., Seite 1780-1787 |
| ISSN Quelle: | 1528-0020 |
| Abstract: | The multicenter, phase 3 German-Speaking Myeloma Multicenter Group (GMMG) ReLApsE trial randomized patients with relapsed and/or refractory multiple myeloma (RRMM) equally to lenalidomide/dexamethasone (LEN/DEX; 25 mg days 1-21, DEX 40 mg weekly, in 4-week cycles) reinduction, salvage high-dose chemotherapy (sHDCT; melphalan 200 mg/m2), autologous stem cell transplantation (ASCT), and LEN maintenance (10 mg/d; transplant arm, n = 139) vs continuous LEN/DEX (control arm, n = 138). Ninety-four percent of patients had received frontline HDCT/ASCT. We report an updated analysis of survival end points with a median follow-up of 99 months. Median progression-free survival (PFS) was 20.5 and 19.3 months in the transplant and control arm, respectively (hazard ratio [HR], 0.98; P = .9). Median overall survival (OS) was 67.1 and 62.7 months, respectively, (HR 0.89; P = .44). Landmark analyses from sHDCT and the contemporaneous LEN/DEX cycle 5 were performed because of 29% dropout of patients before sHDCT/ASCT in the transplant arm but did not reveal significant differences in PFS/OS. Time to progression after frontline HDCT/ASCT was a prognostic factor but did not predict benefit from sHDCT/ASCT. The GMMG ReLApsE trial does not support use of sHDCT/ASCT in RRMM after frontline HDCT/ASCT. This trial was registered at www.clinicaltrialsregister.eu as #EudraCT2009-013856-61. |
| DOI: | doi:10.1182/blood.2024027342 |
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt. Volltext: https://doi.org/10.1182/blood.2024027342 |
| DOI: https://doi.org/10.1182/blood.2024027342 | |
| Datenträger: | Online-Ressource |
| Sprache: | eng |
| K10plus-PPN: | 1927316596 |
| Verknüpfungen: | → Zeitschrift |
